The global hypertrophic cardiomyopathy therapeutics market size was estimated at USD 1.43 billion in 2025 and is projected to reach USD 2.16 billion by 2033, growing at a CAGR of 5.5% from 2026 to 2033. The industry is expanding due to the increasing adoption of targeted pharmacological therapies that address underlying disease mechanisms.
The introduction of cardiac myosin inhibitors has shifted treatment strategies toward disease modification rather than symptom control, supporting long-term clinical management. Rising diagnosis rates driven by advanced imaging technologies and genetic testing have broadened the pool of identifiable patients across age groups. Greater clinical awareness among cardiologists has encouraged earlier intervention. For instance, in January 2025, The Guardian reported that hypertrophic cardiomyopathy, affecting one in 500 people, had been underdiagnosed in women due to a uniform 15 mm wall thickness threshold used for 50 years. Two in three diagnosed patients were men, although women were equally likely to have the condition. A study of 1,600 patients improved female identification by 20 percentage points, and analysis of over 43,000 individuals showed women represented 44 percent under personalized criteria. Improved monitoring and specialty distribution networks further support sustained market growth globally.
Another major growth driver is the continuous advancement of clinical research and product innovation within the cardiovascular therapeutics pipeline. Pharmaceutical companies are investing in next-generation sarcomere modulators, novel small molecules, and precision medicine approaches designed to improve efficacy and safety profiles. For instance, in February 2026, Elsevier published “Mavacamten and Aficamten in Hypertrophic Cardiomyopathy” on ScienceDirect, stating that hypertrophic cardiomyopathy was defined by left ventricular hypertrophy and myocyte disarray. The article reviewed the roles of mavacamten and aficamten in modifying disease processes rather than only addressing symptoms, and discussed phase 2 and phase 3 studies involving adults with obstructive and nonobstructive phenotypes with sample sizes in the thousands. It referenced reductions in left ventricular outflow tract gradients and improvements in exercise capacity and quality of life compared with placebo benchmarks, highlighting numerical endpoints that supported therapeutic shifts. Expanding clinical validation and regulatory progress continue to accelerate commercial uptake across major pharmaceutical markets.
The market is further supported by the growing burden of cardiovascular disorders and increased recognition of genetic cardiomyopathies in aging populations worldwide. Lifestyle related risk factors, including hypertension and metabolic conditions, have contributed to more frequent cardiac assessments and incidental diagnosis of hypertrophic cardiomyopathy. For instance, in July 2024, Medicom Medical Publishers reported on the phase 3 SEQUOIA-HCM trial evaluating aficamten in obstructive hypertrophic cardiomyopathy. The study enrolled 282 participants randomized 1:1 to aficamten plus standard of care or placebo. Eligibility criteria included a left ventricular outflow tract gradient ≥30 mmHg and Valsalva ≥50 mmHg, New York Heart Association class II or III symptoms, and predicted peak oxygen uptake ≤90% for age and sex. At week 24, peak oxygen uptake improved by +1.8 mL/kg/min versus 0.0 mL/kg/min, with a least-squares mean difference of 1.74 mL/kg/min, 95% CI 1.0 to 2.4, P=0.000002, supporting sustained therapeutic adoption globally.
This product will be delivered within 1-3 business days.
The introduction of cardiac myosin inhibitors has shifted treatment strategies toward disease modification rather than symptom control, supporting long-term clinical management. Rising diagnosis rates driven by advanced imaging technologies and genetic testing have broadened the pool of identifiable patients across age groups. Greater clinical awareness among cardiologists has encouraged earlier intervention. For instance, in January 2025, The Guardian reported that hypertrophic cardiomyopathy, affecting one in 500 people, had been underdiagnosed in women due to a uniform 15 mm wall thickness threshold used for 50 years. Two in three diagnosed patients were men, although women were equally likely to have the condition. A study of 1,600 patients improved female identification by 20 percentage points, and analysis of over 43,000 individuals showed women represented 44 percent under personalized criteria. Improved monitoring and specialty distribution networks further support sustained market growth globally.
Another major growth driver is the continuous advancement of clinical research and product innovation within the cardiovascular therapeutics pipeline. Pharmaceutical companies are investing in next-generation sarcomere modulators, novel small molecules, and precision medicine approaches designed to improve efficacy and safety profiles. For instance, in February 2026, Elsevier published “Mavacamten and Aficamten in Hypertrophic Cardiomyopathy” on ScienceDirect, stating that hypertrophic cardiomyopathy was defined by left ventricular hypertrophy and myocyte disarray. The article reviewed the roles of mavacamten and aficamten in modifying disease processes rather than only addressing symptoms, and discussed phase 2 and phase 3 studies involving adults with obstructive and nonobstructive phenotypes with sample sizes in the thousands. It referenced reductions in left ventricular outflow tract gradients and improvements in exercise capacity and quality of life compared with placebo benchmarks, highlighting numerical endpoints that supported therapeutic shifts. Expanding clinical validation and regulatory progress continue to accelerate commercial uptake across major pharmaceutical markets.
The market is further supported by the growing burden of cardiovascular disorders and increased recognition of genetic cardiomyopathies in aging populations worldwide. Lifestyle related risk factors, including hypertension and metabolic conditions, have contributed to more frequent cardiac assessments and incidental diagnosis of hypertrophic cardiomyopathy. For instance, in July 2024, Medicom Medical Publishers reported on the phase 3 SEQUOIA-HCM trial evaluating aficamten in obstructive hypertrophic cardiomyopathy. The study enrolled 282 participants randomized 1:1 to aficamten plus standard of care or placebo. Eligibility criteria included a left ventricular outflow tract gradient ≥30 mmHg and Valsalva ≥50 mmHg, New York Heart Association class II or III symptoms, and predicted peak oxygen uptake ≤90% for age and sex. At week 24, peak oxygen uptake improved by +1.8 mL/kg/min versus 0.0 mL/kg/min, with a least-squares mean difference of 1.74 mL/kg/min, 95% CI 1.0 to 2.4, P=0.000002, supporting sustained therapeutic adoption globally.
Global Hypertrophic Cardiomyopathy Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global hypertrophic cardiomyopathy therapeutics market report based on drug class, disease type, route of administration, distribution channel, and region:Drug Class Outlook (Revenue, USD Million, 2021-2033)
- Beta Blockers
- Calcium Channel Blockers
- Antiarrhythmic Drugs
- Cardiac Myosin Inhibitors
- Anticoagulants
- Others
Disease Type Outlook (Revenue, USD Million, 2021-2033)
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Route of Administration Outlook (Revenue, USD Million, 2021-2033)
- Oral
- Injectable / Parenteral
- Others
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hypertrophic Cardiomyopathy Therapeutics Market Variables, Trends, & Scope
Chapter 4. Hypertrophic Cardiomyopathy Therapeutics Market: Drug Class Business Analysis
Chapter 5. Hypertrophic Cardiomyopathy Therapeutics Market: Disease Type Business Analysis
Chapter 6. Hypertrophic Cardiomyopathy Therapeutics Market: Route of Administration Business Analysis
Chapter 7. Hypertrophic Cardiomyopathy Therapeutics Market: Distribution Channel Business Analysis
Chapter 8. Hypertrophic Cardiomyopathy Therapeutics Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Bristol Myers Squibb
- Cytokinetics, Inc.
- Novartis AG
- Sanofi
- Bayer AG
- Tenaya Therapeutics
- Imbria Pharmaceuticals
- Rocket Pharmaceuticals
- Lexeo Therapeutics
- Edgewise Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.43 Billion |
| Forecasted Market Value ( USD | $ 2.16 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
